Our offering
Supporting access to therapies for rare indications is crucial in navigating the current trends in rare disease treatment approval. Our expertise in the European healthcare market access and specialized market access services ensures successful commercialization of orphan drugs. With insights into emerging trends in orphan drug approvals, we provide expert consultancy for rare disease drug approval.
Flexible market access resourcing for lean teams
We work closely with you to develop tailored market entry strategies, ensuring your rare disease product reaches its target audience effectively.
Key payer & KOL relationships
We leverage our extensive network to facilitate interactions and create partnerships with key payers and key healthcare providers.
Country level access support
We assist in securing fair and sustainable reimbursement for your products at country level, making them accessible to those who need them most.
Commercialization
We develop tailored market strategies to enhance the commercialization of rare disease therapies. Our approach ensures efficient access and long-term success in the healthcare market.
ENTRI key services
- Engaging with local stakeholders in local language
- Creating early KOL support
- Working with patient
- Organizations/patients to get their input and support
- Managing local partners for the preparation and execution as needed
- Investigating possibilities for Managed Entry Agreements and preparing deal structures
- Achieving reimbursement, price and access
- Starting the collection of local data: EHR, RWE, Biobank, Surveys.
Our ENTRI experts
Discover seamless market entry for rare disease treatments with our expert guidance, ensuring maximum impact and accessibility.